Physician profile
Imran M Abassi
NPI 1003875014
$1,078.21
in general payments reported to CMS, 2019-2025
14 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Geriatric Psychiatry provider received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2021: $96.22 · 2022: $102 · 2023: $248 · 2024: $64.93 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $765.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $200.99 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $152.03 | 2022-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $127.40 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $127.14 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $122.90 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $99.91 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $64.25 | 2023-2025 | Trintellix |
| Exelixis INC. | $49.12 | 2023 | Cabometyx |
| Collegium Pharmaceutical, INC. | $44.69 | 2025 | Jornay Pm |
| Alkermes, INC. | $24.93 | 2025 | Aristada, Lybalvi |
| Tris Pharma INC | $22.27 | 2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $14.70 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.63 | 2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Abassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.